New Science, the growth engine for the biopharma industry, helped us get through the pandemic, but inevitably added complexity and cost. The industry’s ability to adapt, lead, and thrive has activated a mindset shift from operational efficiency in individual silos, to resiliency through collaboration across silos and innovation at speed. It must be a multi-disciplinary task between R&D, regulatory affairs, procurement, manufacturing, quality, logistics and supply chain planners, united to deliver and create a more agile, resilient and sustainable pharma supply chain.
Accenture has the experience to help create future-ready life sciences supply chains that deliver across three key priorities:
Relevant – agile and customer-centric, addressing demand changes and scientific advances in a cost effective way
Resilient – preparing for, mitigating and responding to disruptions of all scales and constantly adapting to the ever-increasing complexity of New Science
Responsible – converting scientific advances to high quality medicines available globally by building sustainable value chains, positively impacting society and the planet while enhancing trust
Discover how we can help you sustain life sciences supply chain operations today and mobilize for tomorrow’s scientific advances and growth.
A new era in supply chain CMO collaboration
According to our research, 60% of life sciences supply chain executives (pharma/biopharma/medical device) struggle to get real-time inventory and visibility from external manufacturing partners. And yet, nearly all of them plan to expand their use of contract manufacturers in the next three years. This growth and increased complexity in life sciences supply chains requires an entirely different approach to collaboration to meet the demands of New Science and personalized treatments and devices.
In this report we bring to light the similarities and differences in the challenges both parties face and share real-world examples of where digital technology can help solve collaboration pain points. The report features companies who are getting it right and four key steps to establish a new level of supply chain collaboration.
Our supply chain & operations capabilities are designed to help clients achieve visibility and act with agility now to become a more responsive and resilient organization.
Tackle your greatest sustainability challenges and realize the competitive advantage and impact at scale.
A game-changing pharma supply chain network
When the pandemic struck, developing and deploying effective and safe vaccines as quickly as possible was a top priority. Pharmaceutical companies mobilized to create, test and get vaccines out the door to millions of people rapidly and safely. One leading biopharmaceutical company set out to be the first, rapidly developing a mRNA-based drug. Working in parallel they needed to scale up manufacturing and build a new supply chain network at record speed. As drug development progressed it became clear a game-changing new supply chain network was needed to enable lightspeed delivery and safe handling of a unique new cold chain drug. By identifying current state bottlenecks, automation opportunities and continuous improvement opportunities, we’ve helped prepare the company for ongoing vaccine supply, new formulation launches and created a blueprint for rapid future mRNA product launches.
Accenture supply chain services helps life sciences companies build streamlined supply chains to increase profitability and respond to market challenges. Here are some of our thought leaders weighing in on the topic.
Operations resilience is more than having business continuity plans, rather it is focused on supporting current and future business ambitions. Intentional actions towards resilient operations position companies for growth and agility.
The global pandemic, geopolitical destabilizations and climate challenge our clients’ supply chains and operations. There is an opportunity to take the learnings and technological advances to drive greater resiliency. Resilience is essential for the industry to continue to shatter orthodoxy and create new pathways for innovation, access and affordability.
Yes. Life sciences companies can achieve operations resilience by developing a blueprint to define the path, designing and implementing the workforce, business process and technology backbone and operationalize to sustain value and redirect key talent to strategic efforts.